series-b
Stage
2020
Founded
2
Investors
About
Sparrow Pharmaceuticals is a clinical-stage biotechnology company developing novel, targeted therapies for serious autoimmune and inflammatory conditions. Their lead product candidate, SPI-62, is an HSD-1 inhibitor currently in Phase 2 clinical trials.
Explore Sparrow Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.